Kopp Investment Advisors LLC reduced its position in Enzo Biochem, Inc. (NYSE:ENZ) by 4.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,427 shares of the medical research company’s stock after selling 7,300 shares during the quarter. Enzo Biochem makes up approximately 1.3% of Kopp Investment Advisors LLC’s portfolio, making the stock its 29th biggest position. Kopp Investment Advisors LLC owned 0.34% of Enzo Biochem worth $1,291,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Magnetar Financial LLC acquired a new position in Enzo Biochem in the 3rd quarter valued at about $121,000. LMR Partners LLP acquired a new position in Enzo Biochem in the 3rd quarter valued at about $149,000. Stone Ridge Asset Management LLC acquired a new position in shares of Enzo Biochem during the fourth quarter worth about $135,000. SG Americas Securities LLC acquired a new position in shares of Enzo Biochem during the fourth quarter worth about $181,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Enzo Biochem during the third quarter worth about $263,000. 65.78% of the stock is owned by institutional investors.
In other news, CFO Barry W. Weiner sold 11,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total transaction of $85,250.00. Following the completion of the transaction, the chief financial officer now directly owns 1,313,111 shares of the company’s stock, valued at $10,176,610.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Elazar Rabbani sold 14,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the transaction, the chief executive officer now directly owns 1,867,202 shares of the company’s stock, valued at $14,470,815.50. The disclosure for this sale can be found here. Insiders own 8.90% of the company’s stock.
Enzo Biochem, Inc. (NYSE ENZ) opened at $7.21 on Monday. Enzo Biochem, Inc. has a 52-week low of $6.31 and a 52-week high of $12.04. The company has a market capitalization of $338.33, a PE ratio of -240.33 and a beta of 0.84.
Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The business had revenue of $27.68 million during the quarter, compared to the consensus estimate of $27.51 million.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.